EUROPEAN PHARMACEUTICAL MARKET ACCESS, PRICING & REIMBURSEMENT

    2019

    Start date: October 10, 2016

    End date: October 11, 2016

    Location: London, UK

    UK

    As pharmaceutical global spending is predicted to increase by 29-32% by 2020*, the need for access to cheaper alternative medicines and technology is essential. The use of generics is on the rise and it’s expected that by 2020, 88%* of total medicine use will be attributed to generics, over the counter, and non-original branded products. Source:http://bit.ly/1jb3s88

    This year’s agenda will have a strong focus on the future of pricing and reimbursement. Other key topics include:

    • Updates on AMNOG and its implication on pricing and reimbursement
    • How biosimilars are affecting your pricing strategy
    • Capture on emerging markets’ regulatory framework to adapt your market access and P&R models
    • Orphan drugs using recent examples to highlight the impact on pricing
    • Cancer drug funding and budget cuts in the UK
    • Innovative solutions beyond the pill
    • Japanese and Turkish regional updates